FDA/CDC

FDA okays ubrogepant for acute migraine treatment


 

The Food and Drug Administration has approved ubrogepant (Ubrelvy, Allergan) for the acute treatment of migraine with or without aura in adults.

A stamp saying "FDA approved." Olivier Le Moal/Getty Images

Ubrogepant is the first drug in the class of oral calcitonin gene–related peptide receptor antagonists approved for the acute treatment of migraine. It is approved in two dose strengths (50 mg and 100 mg).

The drug is not indicated, however, for the preventive treatment of migraine.

“Migraine is an often disabling condition that affects an estimated 37 million people in the U.S.,” Billy Dunn, MD, acting director of the office of neuroscience in the FDA’s Center for Drug Evaluation and Research, said in an FDA news release.

Ubrogepant represents “an important new option for the acute treatment of migraine in adults, as it is the first drug in its class approved for this indication. The FDA is pleased to approve a novel treatment for patients suffering from migraine and will continue to work with stakeholders to promote the development of new safe and effective migraine therapies,” added Dr. Dunn.

The safety and efficacy of ubrogepant for the acute treatment of migraine was demonstrated in two randomized, double-blind, placebo-controlled trials (ACHIEVE I and ACHIEVE II). In total, 1,439 adults with a history of migraine, with and without aura, received ubrogepant to treat an ongoing migraine.

“Both 50-mg and 100-mg dose strengths demonstrated significantly greater rates of pain freedom and freedom from the most bothersome migraine-associated symptom at 2 hours, compared with placebo,” Allergan said in a news release announcing approval.

The most common side effects reported by patients in the clinical trials were nausea, tiredness, and dry mouth. Ubrogepant is contraindicated for coadministration with strong CYP3A4 inhibitors.

The company expects to have ubrogepant available in the first quarter of 2020.

A version of this story originally appeared on Medscape.com.

Recommended Reading

Quarterly intravenous eptinezumab prevents migraine
MDedge Family Medicine
Treatment of episodic cluster headache deviates from recommendations
MDedge Family Medicine
Lasmiditan is associated with driving impairment
MDedge Family Medicine
Asthma hospitalization in kids linked with doubled migraine incidence
MDedge Family Medicine
Ubrogepant shows acute migraine efficacy in triptan nonresponders
MDedge Family Medicine
FDA approves Reyvow for acute migraine treatment
MDedge Family Medicine
Children may develop prolonged headache after concussion
MDedge Family Medicine
Ubrogepant may relieve migraine pain at 2 hours
MDedge Family Medicine
Researchers describe first cases of episodic visual snow associated with migraine
MDedge Family Medicine
More phase 3 ubrogepant data published as FDA decision nears
MDedge Family Medicine